Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Long-term clinical, immunological and virological outcomes of patients on antiretroviral therapy in southern Myanmar.

Bermúdez-Aza EH, Shetty S, Ousley J, Kyaw NTT, Soe TT, Soe K, Mon PE, Tun KT, Ciglenecki I, Cristofani S, Fernandez M.

PLoS One. 2018 Feb 8;13(2):e0191695. doi: 10.1371/journal.pone.0191695. eCollection 2018.

2.

Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe.

Judd A, Lodwick R, Noguera-Julian A, Gibb DM, Butler K, Costagliola D, Sabin C, van Sighem A, Ledergerber B, Torti C, Mocroft A, Podzamczer D, Dorrucci M, De Wit S, Obel N, Dabis F, Cozzi-Lepri A, García F, Brockmeyer NH, Warszawski J, Gonzalez-Tome MI, Mussini C, Touloumi G, Zangerle R, Ghosn J, Castagna A, Fätkenheuer G, Stephan C, Meyer L, Campbell MA, Chene G, Phillips A; Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.

HIV Med. 2017 Mar;18(3):171-180. doi: 10.1111/hiv.12411. Epub 2016 Sep 14.

3.

The successful application of a national peer advisory committee for physicians who provide salvage regimens to heavily antiretroviral-experienced patients in mexican human immunodeficiency virus clinics.

Calva JJ, Sierra-Madero J, Soto-Ramírez LE, Aguilar-Salinas P.

Open Forum Infect Dis. 2014 Sep 10;1(2):ofu081. doi: 10.1093/ofid/ofu081. eCollection 2014 Sep.

4.

Long-term virological outcome in children on antiretroviral therapy in the UK and Ireland.

Duong T, Judd A, Collins IJ, Doerholt K, Lyall H, Foster C, Butler K, Tookey P, Shingadia D, Menson E, Dunn DT, Gibb DM; Collaborative HIV Paediatric Study Steering Committee.

AIDS. 2014 Oct 23;28(16):2395-405.

5.

Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch.

Johnston V, Cohen K, Wiesner L, Morris L, Ledwaba J, Fielding KL, Charalambous S, Churchyard G, Phillips A, Grant AD.

J Infect Dis. 2014 Mar 1;209(5):711-20. doi: 10.1093/infdis/jit411. Epub 2013 Aug 13.

6.

HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa.

Eaton JW, Johnson LF, Salomon JA, Bärnighausen T, Bendavid E, Bershteyn A, Bloom DE, Cambiano V, Fraser C, Hontelez JA, Humair S, Klein DJ, Long EF, Phillips AN, Pretorius C, Stover J, Wenger EA, Williams BG, Hallett TB.

PLoS Med. 2012;9(7):e1001245. doi: 10.1371/journal.pmed.1001245. Epub 2012 Jul 10.

7.

Second-line antiretroviral therapy in a workplace and community-based treatment programme in South Africa: determinants of virological outcome.

Johnston V, Fielding K, Charalambous S, Mampho M, Churchyard G, Phillips A, Grant AD.

PLoS One. 2012;7(5):e36997. doi: 10.1371/journal.pone.0036997. Epub 2012 May 29.

8.

Neuropsychiatric complications of aging with HIV.

Watkins CC, Treisman GJ.

J Neurovirol. 2012 Aug;18(4):277-90. doi: 10.1007/s13365-012-0108-z. Epub 2012 May 30. Review.

9.

CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE.

Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord, Young J, Psichogiou M, Meyer L, Ayayi S, Grabar S, Raffi F, Reiss P, Gazzard B, Sharland M, Gutierrez F, Obel N, Kirk O, Miro JM, Furrer H, Castagna A, De Wit S, Muñoz J, Kjaer J, Grarup J, Chêne G, Bucher H.

PLoS Med. 2012;9(3):e1001194. doi: 10.1371/journal.pmed.1001194. Epub 2012 Mar 20.

10.

Determinants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV: a multilevel analysis.

Girardi E, Scognamiglio P, Angeletti C, Gori A, Buonfrate D, Arlotti M, Mazzarello G, Castagna A, Andreoni M, d'Arminio Monforte A, Antinori A, Ippolito G; I.Co.Na Foundation Study.

BMC Health Serv Res. 2012 Feb 15;12:38. doi: 10.1186/1472-6963-12-38.

11.

Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects.

Codoñer FM, Pou C, Thielen A, García F, Delgado R, Dalmau D, Álvarez-Tejado M, Ruiz L, Clotet B, Paredes R.

PLoS One. 2011;6(5):e19461. doi: 10.1371/journal.pone.0019461. Epub 2011 May 13.

12.

Risk of triple-class virological failure in children with HIV: a retrospective cohort study.

Pursuing Later Treatment Options II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE), Castro H, Judd A, Gibb DM, Butler K, Lodwick RK, van Sighem A, Ramos JT, Warsawski J, Thorne C, Noguera-Julian A, Obel N, Costagliola D, Tookey PA, Colin C, Kjaer J, Grarup J, Chene G, Phillips A.

Lancet. 2011 May 7;377(9777):1580-7. doi: 10.1016/S0140-6736(11)60208-0. Epub 2011 Apr 20.

13.

Predictors for the emergence of the 2 multi-nucleoside/nucleotide resistance mutations 69 insertion and Q151M and their impact on clinical outcome in the Swiss HIV cohort study.

Scherrer AU, von Wyl V, Joos B, Klimkait T, Bürgisser P, Yerly S, Böni J, Ledergerber B, Günthard HF; Swiss HIV Cohort Study.

J Infect Dis. 2011 Mar 15;203(6):791-7. doi: 10.1093/infdis/jiq130. Epub 2011 Feb 1.

Supplemental Content

Support Center